Minna Mutka
Overview
Explore the profile of Minna Mutka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
27
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Turpin R, Peltonen K, Rannikko J, Liu R, Kumari A, Nicorici D, et al.
Oncoimmunology
. 2025 Feb;
14(1):2466305.
PMID: 39960413
Tumor-resident immune cells play a crucial role in eliciting anti-tumor immunity and immunomodulatory drug responses, yet these functions have been difficult to study without tractable models of the tumor immune...
2.
Turpin R, Liu R, Munne P, Peura A, Rannikko J, Philips G, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38604809
Background: Combining cytotoxic chemotherapy or novel anticancer drugs with T-cell modulators holds great promise in treating advanced cancers. However, the response varies depending on the tumor immune microenvironment (TIME). Therefore,...
3.
Mutka M, Joensuu K, Heiskala M, Eray M, Heikkila P
Virchows Arch
. 2023 May;
483(2):215-224.
PMID: 37222841
Core needle biopsies (CNB) are widely used to diagnose breast cancer, but the procedure is invasive and thus, it changes the tumor microenvironment. The purpose of this study is to...
4.
Mutka M, Joensuu K, Eray M, Heikkila P
Diagn Pathol
. 2023 Jan;
18(1):3.
PMID: 36627701
Background: Much is known about tumor infiltrating lymphocytes (Tils) in primary breast cancer, as this has been the focus of much research in recent years, but regarding recurrent breast cancer,...
5.
Mutka M, Virtakoivu R, Joensuu K, Hollmen M, Heikkila P
Breast Cancer Res Treat
. 2022 Aug;
195(3):237-248.
PMID: 35917053
Purpose: Common Lymphatic Endothelial and Vascular Endothelial Receptor 1 (Clever-1) is expressed by a subset of immunosuppressive macrophages and targeting the receptor with therapeutic antibodies has been shown to activate...
6.
Munne P, Martikainen L, Raty I, Bertula K, Nonappa , Ruuska J, et al.
Nat Commun
. 2021 Nov;
12(1):6967.
PMID: 34845227
Breast cancer is now globally the most frequent cancer and leading cause of women's death. Two thirds of breast cancers express the luminal estrogen receptor-positive (ERα + ) phenotype that...